Ajooni Biotech Limited (AJOONI.NS)
INR 7.29
(-2.15%)
INR 7.29
(-2.15%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -40.07 Million | -55.79 Million | 36.83 Million | 11.55 Million | -43.84 Million | -49.18 Million |
| Net Income | 21.61 Million | 15.76 Million | 14.61 Million | 5.04 Million | 4.8 Million | 4.1 Million |
| Depreciation & Amortization | 8.74 Million | 10.04 Million | 11.1 Million | 4.36 Million | 3.51 Million | 4.38 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -73.35 Million | -80.93 Million | 7.17 Million | -3.59 Million | -54.99 Million | -50.41 Million |
| Other non-cash items | 113.49 Million | -676 Thousand | 3.94 Million | 5.74 Million | 2.83 Million | -7.26 Million |
| Investing Cash Flow | 71.35 Million | -158.24 Million | -18.97 Million | -34.09 Million | 4.74 Million | -6.5 Million |
| Investments in PPE | -56.01 Million | -28.6 Million | -21.24 Million | -35.26 Million | -14 Million | -2.83 Million |
| Acquisitions | 344 Thousand | 40 Thousand | 990.65 Thousand | - | - | - |
| Investment purchases | - | -131.72 Million | -990.65 Thousand | - | - | -6.5 Million |
| Sales/Maturities of investments | 127.03 Million | -40 Thousand | 1.27 Million | 1.17 Million | 18.02 Million | - |
| Other Investing Activities | 132.38 Million | 2.08 Million | 996.35 Thousand | 2137.00 | 727.44 Thousand | 2.83 Million |
| Financing Cash Flow | -30.09 Million | 216.55 Million | -19.73 Million | 23.74 Million | 33.03 Million | -11.23 Million |
| Debt repayment | -30.09 Million | -1.73 Million | -14.33 Million | -17.58 Million | -2.56 Million | -35.81 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 223.06 Million | - | 12 Million | 33.75 Million | 24.57 Million |
| Other Financing Activities | -35.01 Million | -4.78 Million | -5.4 Million | 29.32 Million | 1.84 Million | 5620.20 |
| Accounts receivables | 75.91 Million | -67.1 Million | -1.28 Million | -10.69 Million | -78.08 Million | -19.71 Million |
| Accounts payables | -85.26 Million | 33.11 Million | - | - | 7.68 Million | - |
| Inventory | -83.73 Million | -11.12 Million | -5.05 Million | -20.9 Million | 17.83 Million | -30.69 Million |
| Other working capital | 19.72 Million | -35.81 Million | 13.51 Million | 28 Million | -2.43 Million | -3.18 Million |
| Cash at beginning of period | 3.09 Million | 574 Thousand | 2.44 Million | 1.23 Million | 7.3 Million | 52.96 Million |
| Cash at end of period | 4.28 Million | 3.09 Million | 573.85 Thousand | 2.44 Million | 1.23 Million | 7.3 Million |
| Capital Expenditure | -56.01 Million | -28.6 Million | -21.24 Million | -35.26 Million | -14 Million | -2.83 Million |
| Effect of forex changes on cash | - | -1000.00 | 144.73 | -0.49 | -0.48 | 21.25 Million |
| Net cash flow / Change in cash | 1.18 Million | 2.51 Million | -1.86 Million | 1.2 Million | -6.06 Million | -45.66 Million |
| Free Cash Flow | -96.09 Million | -84.39 Million | 15.59 Million | -23.71 Million | -57.85 Million | -52.02 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 9.14 Million | 21.61 Million | 4.39 Million | 4.04 Million | 4.01 Million | 15.76 Million |
| Depreciation & Amortization | - | 8.74 Million | 2.13 Million | 2.13 Million | 2.09 Million | 10.04 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -73.35 Million | - | - | - | -80.93 Million |
| Other non-cash items | -9.14 Million | 113.49 Million | -4.39 Million | -4.04 Million | -4.01 Million | -676 Thousand |
| Investing Cash Flow | - | 71.35 Million | - | - | - | -158.24 Million |
| Investments in PPE | - | -56.01 Million | - | - | - | -28.6 Million |
| Acquisitions | - | 344 Thousand | - | - | - | 40 Thousand |
| Investment purchases | - | - | - | - | - | -131.72 Million |
| Sales/Maturities of investments | - | 127.03 Million | - | - | - | -40 Thousand |
| Other Investing Activities | - | 132.38 Million | - | - | - | 2.08 Million |
| Financing Cash Flow | - | -30.09 Million | - | - | - | 216.55 Million |
| Debt repayment | - | -30.09 Million | - | - | - | -1.73 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | 223.06 Million |
| Other Financing Activities | - | -35.01 Million | - | - | - | -4.78 Million |
| Accounts receivables | - | 75.91 Million | - | - | - | -67.1 Million |
| Accounts payables | - | -85.26 Million | - | - | - | 33.11 Million |
| Inventory | - | -83.73 Million | - | - | - | -11.12 Million |
| Other working capital | - | 19.72 Million | - | - | - | -35.81 Million |
| Cash at beginning of period | - | 3.09 Million | 2.77 Million | 23.14 Million | 3.09 Million | 574 Thousand |
| Cash at end of period | - | 4.28 Million | 13.58 Million | 2.77 Million | 23.14 Million | 3.09 Million |
| Capital Expenditure | - | -56.01 Million | - | - | - | -28.6 Million |
| Effect of forex changes on cash | - | - | - | - | - | -1000.00 |
| Net cash flow / Change in cash | - | 1.18 Million | 10.81 Million | -20.37 Million | 20.05 Million | 2.51 Million |
| Free Cash Flow | - | -96.09 Million | 4.26 Million | 4.26 Million | 4.18 Million | -84.39 Million |
688518
KANORICHEM
8349
8622
EU
0237